References

Bansal, S. and V. Tandon, 2011. Contribution of mutations in DNA gyrase and topoisomerase IV genes to ciprofloxacin resistance in Escherichia coli clinical isolates. Int. J. Antimicrob. Agents, 37: 253-255.
CrossRef  |  

Barger, A., C. Fuhst and B. Wiedemann, 2003. Pharmacological indices in antibiotic therapy. J. Antimicrobial Chemother., 52: 893-898.
CrossRef  |  

Begic, D., C. von Eiff and B.T. Tsuji, 2009. Daptomycin pharmacodynamics against Staphylococcus aureus hemB mutants displaying the small colony variant phenotype. J. Antimicrobial Chemother., 63: 977-981.
CrossRef  |  

Booker, B.M., P.F. Smith, A. Forrest, J. Bullock and P. Kelchlin et al., 2005. Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype typhi. Antimicrobial Agents Chemother., 49: 1775-1781.
PubMed  |  

Coulet, M., M.V.B. Waalkes, P. Cox and J. Lohuis, 2002. In vitro and in vivo pharmacodynamic properties of the fluoroquinolone ibafloxacin. J. Vet. Pharmacol. Therapeutics, 25: 401-411.
CrossRef  |  

Craig, W.A., 1998. Basic pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin. Infect. Dis., 26: 1-10.
PubMed  |  Direct Link  |  

Dalhoff, A. and F.J. Schmitz, 2003. In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur. J. Clin. Microbiol. Infect. Dis., 22: 203-221.
CrossRef  |  Direct Link  |  

Drago, L., L. Nicola, R. Mattina and E. de Vecchi, 2010. In vitro selection of resistance in Escherichia coli and Klebsiella spp. at in vivo fluoroquinolone concentrations. BMC Microbiol., 10: 119-119.
CrossRef  |  

Everett, M.J., Y.F. Jin, V. Ricci and L.J. Piddock, 1996. Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals. Antimicrob. Agents Chemother., 40: 2380-2386.
PubMed  |  

Ferraro, M.J., 2003. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically: Approved Standard. 6th Edn., NCCLS, USA, ISBN: 9781562384869, Pages: 50.

Gibson, J.S., R.N. Cobbold, M.T. Kyaw-Tanner, P. Heisig and D.J. Trott, 2010. Fluoroquinolone resistance mechanisms in multidrug-resistant Escherichia coli isolated from extraintestinal infections in dogs. Vet. Microbiol., 146: 161-166.
CrossRef  |  

Gloede, J., C. Scheerans, H. Derendorf and C. Kloft, 2010. In vitro pharmacodynamic models to determine the effect of antibacterial drugs. J. Antimicrob. Chemother., 65: 186-201.
PubMed  |  

Hooper, D.C., 2001. Emerging mechanisms of fluoroquinolone resistance. Emerg. Infect. Dis., 7: 337-341.
PubMed  |  Direct Link  |  

Katie, L.H., R.H. Davies and E.J. Threlfall, 2005. Mechanisms of quinolone resistance in Escherichia coli and Salmonella: Recent developments. Int. J. Antimicrob. Agents., 25: 358-373.
CrossRef  |  PubMed  |  Direct Link  |  

Kays, M.B. and G.A. Denys, 2001. Fluoroquinolone susceptibility, resistance and pharmacodynamics versus clinical isolates of Streptococcus pneumoniae from Indiana. Diagn. Microbiol. Infect. Dis., 40: 193-198.
PubMed  |  

Khan, A.A., M.S. Nawaz, C.S. West, S.A. Khan and J. Lin, 2005. Isolation and molecular characterization of fluoroquinolone-resistant Escherichia coli from poultry litter. Poult. Sci., 84: 61-66.
PubMed  |  

Kosowska-Shick, K., C. Clark, G.A. Pankuch, P. McGhee, B. Dewasse, L. Beachel and P.C. Appelbaum, 2009. Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies. Antimicrob. Agents Chemother., 53: 4217-4224.
CrossRef  |  

Lee, Y., J.K. Cho, K. Kim, R. Tak, A. Kim, J. Kim, S. Im and B. Kim, 2005. Fluoroquinolone resistance and gyrA and parC mutations of Escherichia coli isolated from chicken. J. Microbiol., 43: 391-397.
PubMed  |  

Levison, M.E., 2004. Pharmacodynamics of antimicrobial drugs. Infect. Dis. Clin. North Am., 18: 451-465.
CrossRef  |  PubMed  |  Direct Link  |  

Martinez, M., P. McDermott and R. Walker, 2006. Pharmacology of the fluoroquinolones: A perspective for the use in domestic animals. Vet. J., 172: 10-28.
CrossRef  |  

Mueller, M., A. de la Pena and H. Derendorf, 2004. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: Kill curves versus MIC. Antimicrob Agents Chemother., 48: 369-377.
CrossRef  |  PubMed  |  

NCCLS, 2001. Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from Animals. 3rd Edn., National Committee for Clinical Laboratory Standards, Approved Standard M31-A3, Wayne, PA USA.

Olofsson, S.K., L.L. Marcusson, A. Stromback, D. Hughes and O. Cars, 2007. Dose-related selection of fluoroquinolone-resistant Escherichia coli. J. Antimicrob. Chemother., 60: 795-801.
PubMed  |  

Orden, J.A., J.A. Ruiz-Santa-Quiteria, D. Cid, R. Diez, S. Martinez and R. de la Fuente, 2001. Quinolone resistance in potentially pathogenic and non-pathogenic Escherichia coli strains isolated from healthy ruminants. J. Antimicrob. Chemother., 48: 421-424.
PubMed  |  

Owens, R.C. and P.G. Ambrose, 2001. Pharmacodynamics of Quinolones. In: Antimicrobial Pharmacodynamis in Theory and Clinical Practice, Nightingale, C.H., T. Muratawa and P.G. Ambrose (Eds.). Marcel Dekker Inc., Basel, New York, pp: 155.

Ross, G.H., D.H. Wright, L.B. Hovde, M.L. Peterson and J.C. Rotschafer, 2001. Fluoroquinolone resistance in anaerobic bacteria following exposure to levofloxacin, trovafloxacin and sparfloxacin in an in vitro pharmacodynamic model. J. Antimicrob. Chemother., 45: 2136-2140.
CrossRef  |  

Tran, J.H. and G.A. Jacoby, 2002. Mechanism of plasmid-mediated quinolone resistance. Proc. Natl. Acad. Sci. USA., 99: 5638-5642.
PubMed  |  

Tsuji, B.T., C. von Eiff, P.A. Kelchlin, A. Forrest and P.F. Smith, 2008. Attenuated vancomycin bactericidal activity against Staphylococcus aureus hemB mutants expressing the small-colony-variant phenotype. Antimicrob. Agents Chemother., 52: 1533-1537.
PubMed  |  

Tsuji, B.T., J.C. Yang, A. Forrest, P.A. Kelchlin and P.F. Smith, 2008. In vitro pharmacodynamics of novel rifamycin ABI-0043 against Staphylococcus aureus. J. Antimicrob. Chemother., 62: 156-160.
PubMed  |  

Weigel, L.M., C.D. Steward and F.C. Tenover, 1998. GyrA mutations associated with fluoroquinolone resistance in eight species of Enterobacteriaceae. Antimicrob. Agents Chemother., 42: 2661-2667.
PubMed  |  

Zhanel, G.G., D. Roberts, A. Waltky, N. Laing and K. Nichol et al., 2002. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae. J. Antimicrob. Chemother., 49: 807-812.
PubMed  |